Between cycles
See immune decline between visits.
Regular full blood counts track the neutrophil count between visits, supporting earlier action while intervention is safest and least costly.
Learn the sciencePhase 1 · Oncology
Reduce high-cost events.
Protect treatment continuity — support earlier detection of immune decline between cycles, so chemotherapy stays on schedule and avoidable admissions, sepsis and ICU escalations go down.
The opportunity
30 – 40%
Potential reduction in avoidable admissions (modelled)
50,000 – 65,000
UK febrile neutropenia patients a year
£350m – £650m
Estimated annual NHS saving (modelled)
The problem
A signal that arrives too late.
01
Late detection
Around 15 – 20% of chemotherapy patients develop febrile neutropenia, often identified only after an emergency attendance.
02
Reactive testing
Reactive blood tests miss the window where intervention is cheapest and safest.
03
Treatment gaps
Delayed or skipped cycles compromise efficacy and survival.
04
Reduce high-cost events
Avoidable admissions, sepsis and ICU escalations drive most of the cost and most of the harm.
Cycle adherence
Keep treatment on schedule.
Earlier detection means fewer skipped cycles, fewer dose reductions, and fewer avoidable admissions — the things that drive survival.
How it works
At home, every cycle.
A finger-prick cartridge on the Proxima device returns a full blood count without a clinic visit. Results flow to the patient's phone and the clinician's dashboard within minutes.
Meet ProximaHow a cycle looks.
01
Test from home
A single cartridge, under five minutes. No phlebotomist required.
02
Build a baseline
Every test refines the patient's personal reference range.
03
Spot the drift
AI flags meaningful deviation in immune markers.
04
Act early
Care team is alerted to meaningful change early.
Solutions
Bring regular immune monitoring to your patients.
Book a 20-minute briefing with our clinical team to see Algocyte in action.